{"nctId":"NCT01893138","briefTitle":"Autologous Muscle Derived Cells for Female Urinary Sphincter Repair","startDateStruct":{"date":"2013-11-21","type":"ACTUAL"},"conditions":["Stress Urinary Incontinence"],"count":311,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Iltamiocel","type":"EXPERIMENTAL","interventionNames":["Biological: Iltamiocel"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Iltamiocel","otherNames":["Autologous muscle-derived cells (AMDC)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female patient has primary symptoms of SUI, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation.\n\nExclusion Criteria:\n\n* Patient has symptoms of pure urge incontinence as confirmed by basic evaluation of etiology from a patient medical history, including a focused incontinence history.\n* Patient has symptoms of mixed urinary incontinence where urge incontinence is the predominant factor.\n* Patient has had stress urinary incontinence symptoms less than 6 months prior to signing the informed consent.\n* Patient has not previously attempted conservative treatment prior to signing the informed consent. (Examples of conservative treatment include behavior modifications, bladder exercises, biofeedback, etc.)\n* Patient has more than 2 episode of awakening to void during normal sleeping hours.\n* Patient cannot be maintained on a stable dose and/or frequency of medication (including diuretics) known to affect lower urinary tract function, including but not limited to, anticholinergics, tricyclic antidepressants or alpha-adrenergic blockers, for at least 2 weeks prior to screening or is likely to change during the course of the study.\n* Patient is pregnant, lactating, or plans to become pregnant during the course of the study.\n* Patient refuses to provide written informed consent.\n* Patient is not at least 18 years of age.\n* Patient is not available for the follow-up evaluations as required by the protocol.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Frequency of Stress Incontinence Episodes From Baseline at 12 Months","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"11"},{"groupId":"OG001","value":"-4.9","spread":"13.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association of Change in Quality of Life Scores With Change in Stress Incontinence Episode Frequency","description":"Spearman's correlation used for analysis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.556","spread":null},{"groupId":"OG001","value":"-0.456","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.522","spread":null},{"groupId":"OG001","value":"0.442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.408","spread":null},{"groupId":"OG001","value":"0.433","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.537","spread":null},{"groupId":"OG001","value":"0.422","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.529","spread":null},{"groupId":"OG001","value":"0.599","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment Durability at 24 Months","description":"Treatment durability defined as iltamiocel-treated participants with reduction in stress incontinence episode frequency (SIEF) at 12 months who maintained that response at 24 months","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]},{"type":"POST_HOC","title":"Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months (Prior Surgery Participants Only)","description":"Participants with a history of prior SUI surgery with baseline and 12 month diary data.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"POST_HOC","title":"Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months (Prior Surgery Participants Only)","description":"Participants with a history of prior SUI surgery with baseline and 12 month diary data.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"POST_HOC","title":"Change in the Frequency of Stress Incontinence Episodes From Baseline at 12 Months (Prior Surgery Participants Only)","description":"Participants with a history of prior SUI surgery with baseline and 12 month diary data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"14.5"},{"groupId":"OG001","value":"-4.5","spread":"11.5"}]}]}]},{"type":"POST_HOC","title":"Association of Change in Quality of Life Scores With Change in Stress Incontinence Episode Frequency (Prior Surgery Participants Only)","description":"Spearman's correlation used for analysis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.489","spread":null},{"groupId":"OG001","value":"-0.460","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.427","spread":null},{"groupId":"OG001","value":"0.542","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.424","spread":null},{"groupId":"OG001","value":"0.604","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.561","spread":null},{"groupId":"OG001","value":"0.190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.426","spread":null},{"groupId":"OG001","value":"0.476","spread":null}]}]}]},{"type":"POST_HOC","title":"Treatment Durability at 24 Months (Prior Surgery Participants)","description":"Treatment durability defined as participants with reduction in stress incontinence episode frequency (SIEF) at 12 months who maintained response at 24 months","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":199},"commonTop":["Urinary tract infection","Dysuria","Sinusitis","Back pain","Injection site pain"]}}}